SEC Form 4 · accession 0001493152-18-009946
Adhera Therapeutics, Inc. · ATRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Erik Emerson
Officer — Chief Commercial Officer · Director
Period of report
Jul 10, 2018
Accepted (ET)
Jul 12, 2018 · 5:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000737207
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to purchase common stockF1 | $0.66 | Jul 10, 2018 | A | 1,125,000 | A | — | Jul 10, 2028 | common stock | 1,125,000 | 1,125,000 | D |
Explanation of responses
- F1Options to purchase 187,500 shares of common stock are exercisable immediately, options to purchase 187,500 shares of common stock are exercisable on each of July 10, 2019, July 10, 2020 and July 10, 2021, options to purchase 187,500 shares of common stock shall vest on such date, if any, as the Issuer determines that it has achieved net product revenue in the amount of not less than $1.2 million for the portion of the 2018 fiscal year following June 18, 2018, and options to purchase 187,500 shares of common stock shall vest on such date, if any, as the Issuer determines that the daily VWAP of the common stock of the Issuer was not less than $2.00 per share for a sixty consecutive day period beginning on any calendar day during the 2018 fiscal year on or after June 18, 2018.